P79.02 Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLC
C. Zhou(Tongji University), Chengping Hu(Central South University), Xiaoqian Lin(Chinese Academy of Sciences), G. Chen(Harbin Medical University), Ji‐Yuan Zhou(Southern Medical University), Yimin Fan(Zhejiang Cancer Hospital), Yuanqi Chen(Jiangxi Provincial Cancer Hospital), Q. Wang(Henan Cancer Hospital), Zhi-Qing He(Fujian Provincial Cancer Hospital), Shien Hu(Hubei Cancer Hospital), Fan Jin(Second Affiliated Hospital of Xi'an Jiaotong University), Lai Wang(Arog Pharmaceuticals (United States)), Jie Zhao(First Affiliated Hospital of Zhengzhou University), Jiuwei Cui(Jilin University), Lizhu Lin(Guangzhou University of Chinese Medicine), Shuliang Guo(Apple (Israel)), Yi Hu(Union Hospital), W. Zhang(Nanchang University), Jian Huang(Soochow University), J. Chen(Hunan Cancer Hospital), Jianping Xiong(Nanchang University), Z. Wang(Second Affiliated Hospital of Zhejiang University), Jintao Fang(Wenzhou Medical University), Jianxiang Shi, Xue Jiang(Freeman Hospital), Hongjun Gao(Chinese PLA General Hospital), C. Zhu(Wenzhou Medical University), Q. Chen(Fuzhou Pulmonary Hospital of Fujian), Xiangdong Zhou(Army Medical University), Y. Liu(Hong Kong Polytechnic University), Andy Liu(University of Southern California), Yang Wang(University of Science and Technology of China), Jiadong Zhao, Xiubao Ren(Tianjin Medical University Cancer Institute and Hospital), Kangsheng Gu(Anhui Medical University), Ping Lu(California Institute for Regenerative Medicine), Yunchao Huang(North China University of Water Resources and Electric Power), Yongqian Shu(Jiangsu Province Hospital), Jing Huang(Soochow University), X. Dong(Huazhong University of Science and Technology), Yun Pan(University of Science and Technology of China), J. Feng(Hangzhou First People's Hospital), Can Ding(Hebei Medical University), Yuli Cheng(Jilin Province Tumor Hospital), Likui Cao(University of Science and Technology of China), Guangyu An(Yang Hospital), J. Chang(Fudan University Shanghai Cancer Center), Feng Wu(Kunming University of Science and Technology), B. Gao(Ruijin Hospital), Y. Zhang(Zhejiang Cancer Hospital)
Cited by 7
Related Papers
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis
|Cancer Cell|2008|917